New mRNA vaccines to improve T-cell therapies for solid tumors
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors
This study is working on new mRNA vaccines that could help boost treatments for pancreatic cancer by making the immune system's T-cells better at fighting the cancer, and it's aimed at improving outcomes for patients facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10982192 on NIH RePORTER |
What this research studies
This research focuses on developing innovative mRNA vaccines that enhance the effectiveness of T-cell transfer therapies specifically for pancreatic cancer. By utilizing a modified mRNA technology that has shown success in COVID-19 vaccines, the project aims to create vaccines that can better stimulate the immune system's CD8+ T cells to target cancer cells. The research will involve mechanistic studies to optimize the vaccine's design and evaluate its performance in advanced animal models of pancreatic ductal adenocarcinoma. The ultimate goal is to improve treatment outcomes for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with cancers other than pancreatic ductal adenocarcinoma may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results using mRNA technology in cancer immunotherapy, indicating potential for success in this novel application.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Radu, Caius Gabriel — University of California Los Angeles
- Study coordinator: Radu, Caius Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.